Q2
BGLC — Q2 2026 Financial Report Analysis
BioNexus revenue fell 96.6% to $76,156 as its Chemrex chemicals unit shrank after alleged misconduct by former managers; the net loss narrowed to $286,451 on cost cuts, while $800,000 of post-quarter insider stock awards and new share-funded licences point to heavy dilution.